PMID- 23545003
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20151119
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 23
IP  - 5
DP  - 2013 Apr
TI  - [Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms 
      secondary to benign prostatic hyperplasia].
PG  - 283-95
LID - S1166-7087(12)00673-2 [pii]
LID - 10.1016/j.purol.2012.11.009 [doi]
AB  - PURPOSE: The objective of this literature review was to report currently 
      available clinical data on the effects of phosphodiesterase type 5 inhibitors 
      (PDE5I) on lower urinary tract symptoms (LUTS) secondary to benign prostatic 
      hyperplasia (BPH). METHODS: An international literature review was carried out in 
      February 2012 from the Medline database (National Library of Medicine, United 
      States). Studies on the effects of PDE5I on LUTS secondary to BPH published 
      within the last 15 years (1997 to 2012) were extracted. In total, 12 studies were 
      selected: four studies on sildenafil including one randomized, controlled, 
      double-blind study; one randomized, controlled, double-blind study on vardenafil; 
      and seven studies on tadalafil including five randomized, controlled, 
      double-blind studies and a 1-year open-label extension study. RESULTS: PDE5Is 
      significantly improve the overall international prostatic symptom score (IPSS) 
      compared to placebo. Most often, the maximum urinary flow rate (Qmax) was not 
      significantly increased versus placebo. A statistically significant improvement 
      of Qmax was nevertheless observed in certain studies. CONCLUSION: The available 
      clinical data assessing the efficacy of PDE5 inhibition in LUTS secondary to BPH 
      are convincing. PDE5Is thus are a new therapeutic class in the treatment of this 
      disease and are especially interesting in patients suffering from both LUTS and 
      erectile dysfunction (ED), two frequently associated diseases.
CI  - Copyright (c) 2012 Elsevier Masson SAS. All rights reserved.
FAU - Giuliano, F
AU  - Giuliano F
AD  - Neuro-uro-andrologie, service de medecine physique et de readaptation, hopital 
      Raymond-Poincare, faculte des sciences de la sante, universite de Versailles 
      Saint-Quentin-en-Yvelines, 92380 Garches, France. srahal@eltium.fr
FAU - Roupret, M
AU  - Roupret M
FAU - Doridot, G
AU  - Doridot G
FAU - de la Taille, A
AU  - de la Taille A
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
TT  - Effets des inhibiteurs de la phosphodiesterase de type 5 sur les symptomes du bas 
      appareil urinaire associes a une hypertrophie benigne de la prostate.
DEP - 20121228
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
RN  - 0 (Carbolines)
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 742SXX0ICT (Tadalafil)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Carbolines/therapeutic use
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*drug therapy/*etiology
MH  - Male
MH  - Phosphodiesterase 5 Inhibitors/*therapeutic use
MH  - Piperazines/therapeutic use
MH  - Prostatic Hyperplasia/*complications
MH  - Purines/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sildenafil Citrate
MH  - Sulfones/therapeutic use
MH  - Tadalafil
EDAT- 2013/04/03 06:00
MHDA- 2013/10/01 06:00
CRDT- 2013/04/03 06:00
PHST- 2012/08/24 00:00 [received]
PHST- 2012/10/24 00:00 [revised]
PHST- 2012/11/19 00:00 [accepted]
PHST- 2013/04/03 06:00 [entrez]
PHST- 2013/04/03 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
AID - S1166-7087(12)00673-2 [pii]
AID - 10.1016/j.purol.2012.11.009 [doi]
PST - ppublish
SO  - Prog Urol. 2013 Apr;23(5):283-95. doi: 10.1016/j.purol.2012.11.009. Epub 2012 Dec 
      28.